Loading...
Loading...
VALN| Name | Value |
|---|---|
| Revenues | 156.7M |
| Cost of Revenue | 31.2M |
| Gross Profit | 125.4M |
| Operating Expense | 32.2M |
| Operating I/L | 93.3M |
| Other Income/Expense | -21.0M |
| Interest Income | 0.0M |
| Pretax | 72.3M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 72.4M |
Valneva SE is a specialty vaccine company that develops and commercializes prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO for Japanese encephalitis, DUKORAL for cholera and E. coli-induced diarrhea, and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate against Borrelia, and VLA1553, a vaccine candidate against the chikungunya virus. Valneva SE generates revenue by selling its vaccines in various countries and through collaborations with partners such as Pfizer, Inc. and Instituto Butantan for the development and commercialization of vaccines.
